ENDV · Endonovo Therapeutics, Inc. · Shareholders & Ownership
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.”View the 10-Q filed Dec 29, 2023
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Every disclosed holder of ENDV in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns ENDV
| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 0 | 0.00% |
| Insiders (Forms 3, 4, 5) | 0 | 0.00% |
| 13D/G-only blocks | 0 | 0.00% |
| Remaining | 318,751,597 | 100.00% |
| Registered funds (N-PORT, not summed) | 0 | 0.00% |
Shares outstanding: 318,751,597, the issuer's latest cover-page count restated onto today's split basis.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.